Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Development and Utilization of Drug For Treating Psychotic Disorders: How Well Have US Federal and State Policies/ Laws Served Individual and Societal.
ANTIPSYCHOTICS Katy and Zoë. Psychosis Mental disorder with a broad range of symptoms. Patients ‘lose touch with reality’ and present with: hallucinations.
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
WPA Atypical or Second Generation Neuroleptics. WPA Period 4: BPRS Total Score During Double-Blind Period.
Quetiapine Fumarate Quetiapine Fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar.
Nuplazid™ - Pimavanserin
Impulse Control Disorders (ICD) and Parkinson Disease (PD)
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Receptor occupancy and clinical response for antipsychotic agents
Symptom Control and Enhancing Functioning in Schizophrenia
Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.
The Nurse View.
Incorporating New Therapies in IBS-C
Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF
A Multidisciplinary Team Approach Challenges and Best Practices in Cushing Disease.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Bipolar Disorder: Latest Clinical Update
Goals of Therapy for Patients With UC
Glaucoma Progression.
Motor Fluctuations in Parkinson Disease: Options and Strategies
Parkinson Disease:.
Addressing Neuropsychiatric Symptoms in Patients With Dementia
Epidemiology Venous Pathophysiology Etiology.
The Tumor Microenvironment
بسم الله الرحمن الرحيم.
Schizophrenia Treatments With New Mechanisms of Action Are Emerging
Unmet Needs in Schizophrenia
The Parkinson's Disease Psychosis Journal Club
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Managing Depression in Bipolar I Disorder
From Symptom Management to Communication in Advanced GI Cancers
Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
Understanding PAD.
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Demographics of IPF in the USa-d
ADVANCED PARKINSON'S DISEASE:
Best Practices in the Identification and Management of Alzheimer Agitation.
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Live From MDS New Developments in Parkinson's Disease Psychosis
Updates in the Management of Parkinson's Disease Psychosis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Parkinson Disease Psychosis
Maintenance Therapy in Advanced Ovarian Cancer
Antipsychotic (Neuroleptic) Drugs
Understanding and Addressing the Needs of Patients With AD
Treatment-Resistant Schizophrenia
Tackling Schizophrenia With Your Patients
Implications of Emerging Treatments for Beta-Thalassemia
New Approaches to Insomnia Management: Impact on Clinical Practice
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient Questions and Expert Answers in Psoriasis:
What's New in PAH?.
Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Pharmacological Management of Parkinson’s Disease
Communicating With Your Patients About Major Depressive Disorder
Improving Adherence to Antiplatelet Therapy After an ACS Event
Program Goal. Program Goal Disclaimer Overview.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
3 Things to Know About Novel Treatment Targets for Schizophrenia
Emerging Combination Injectable Therapy A New Era in Diabetes Care
Evaluating Success of Current Treatments for HCM
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Understanding the Basics of Dementia-Related Psychosis
Presentation transcript:

Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis

Program Goals

Parkinson Disease Psychosis

Psychosis and Dementia

"Benign" Hallucinations

"Benign" Hallucinations (cont)

Managing Symptoms of Psychosis

Reducing PD Therapies

Take-Home Message: Managing PDP

Atypical Antipsychotics

Clozapine: Efficacy

Clozapine: Adverse Events

Quetiapine

Additional Atypical Antipsychotics

Take-Home Message: Pharmacotherapy

Psychiatrists and Neurologists

Using PD Therapies in PDP

Individualizing Treatment in PDP

PDP and Dopamine

PDP and the Serotonergic System

Inverse Agonists

Atypical Antipsychotics: Mechanism of Action

Pimavanserin

Effect of Emerging Therapies on PDP Treatment

Conclusions: Clinical Practice

Conclusions: Communication

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.